• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The EUTOS score identifies chronic myeloid leukeamia patients with poor prognosis treated with imatinib first or second line.

作者信息

Breccia Massimo, Finsinger Paola, Loglisci Giuseppina, Latagliata Roberto, Mancini Marco, Salaroli Adriano, Serrao Alessandra, Zacheo Irene, Alimena Giuliana

出版信息

Leuk Res. 2012 Sep;36(9):e209-10. doi: 10.1016/j.leukres.2012.05.011. Epub 2012 Jul 6.

DOI:10.1016/j.leukres.2012.05.011
PMID:22770911
Abstract
摘要

相似文献

1
The EUTOS score identifies chronic myeloid leukeamia patients with poor prognosis treated with imatinib first or second line.EUTOS评分可识别出接受伊马替尼一线或二线治疗、预后较差的慢性髓性白血病患者。
Leuk Res. 2012 Sep;36(9):e209-10. doi: 10.1016/j.leukres.2012.05.011. Epub 2012 Jul 6.
2
EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia.EUTOS 评分可预测慢性髓性白血病患者的长期预后，但不能预测伊马替尼的最佳反应。
Leuk Res. 2013 Nov;37(11):1457-60. doi: 10.1016/j.leukres.2013.07.037. Epub 2013 Aug 11.
3
Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy.EUTOS评分与3个月时的BCR-ABL转录水平相结合，可识别出一组对一线伊马替尼治疗反应良好的低风险慢性髓性白血病患者。
Am J Hematol. 2015 Jul;90(7):E135-7. doi: 10.1002/ajh.24022. Epub 2015 May 28.
4
Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting.在常规临床环境中，慢性髓性白血病患者的伊马替尼血浆浓度谷值与治疗反应无关。
Ann Hematol. 2012 Jun;91(6):923-9. doi: 10.1007/s00277-011-1394-x. Epub 2012 Jan 11.
5
Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond.治疗慢性髓性白血病期间的外周血监测：伊马替尼、二线药物及其他药物。
Cancer. 2011 Mar 15;117(6):1245-52. doi: 10.1002/cncr.25678. Epub 2010 Nov 2.
6
Imatinib therapy in chronic myeloid leukemia.伊马替尼治疗慢性粒细胞白血病。
Hematol Oncol Clin North Am. 2004 Jun;18(3):605-17, viii. doi: 10.1016/j.hoc.2004.03.014.
7
Suboptimal response to imatinib according to 2006-2009 European LeukaemiaNet criteria: a 'grey zone' at 3, 6 and 12 months identifies chronic myeloid leukaemia patients who need early intervention.根据2006 - 2009年欧洲白血病网标准，伊马替尼治疗反应欠佳：3个月、6个月和12个月时的“灰色地带”可识别出需要早期干预的慢性髓性白血病患者。
Br J Haematol. 2011 Jan;152(1):119-21. doi: 10.1111/j.1365-2141.2010.08380.x. Epub 2010 Oct 11.
8
Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response.甲磺酸伊马替尼停药用于一线甲磺酸伊马替尼治疗且达到完全分子学缓解的慢性髓性白血病患者。
Leuk Res. 2012 Jun;36(6):689-93. doi: 10.1016/j.leukres.2012.02.011. Epub 2012 Mar 5.
9
Imatinib in chronic myeloid leukemia.伊马替尼治疗慢性髓性白血病
N Engl J Med. 2007 Apr 26;356(17):1780; author reply 1780. doi: 10.1056/NEJMc063767.
10
EUTOS score predicts survival and cytogenetic response in patients with chronic phase chronic myeloid leukemia treated with first-line imatinib.EUTOS评分可预测一线应用伊马替尼治疗的慢性期慢性髓性白血病患者的生存率和细胞遗传学反应。
Leuk Res. 2014 Sep;38(9):1030-5. doi: 10.1016/j.leukres.2014.06.006. Epub 2014 Jun 18.

引用本文的文献

1
Aplasia in Chronic Phase CML Post-TKI Therapy: A Management Dilemma.慢性期慢性粒细胞白血病经酪氨酸激酶抑制剂治疗后的再生障碍：管理困境
Case Rep Hematol. 2019 Sep 22;2019:4861673. doi: 10.1155/2019/4861673. eCollection 2019.
2
Effectiveness of Three Prognostic Scoring Systems in Predicting the Response and Outcome in Pediatric Chronic Myeloid Leukemia Chronic Phase on Frontline Imatinib.三种预后评分系统对儿童慢性粒细胞白血病慢性期一线伊马替尼治疗反应和结局的预测效能
Indian J Med Paediatr Oncol. 2017 Jul-Sep;38(3):282-286. doi: 10.4103/ijmpo.ijmpo_104_16.
3
Consistency Test between Scoring Systems for Predicting Outcomes of Chronic Myeloid Leukemia in a Saudi Population Treated with Imatinib.
沙特接受伊马替尼治疗的慢性髓性白血病患者预后预测评分系统之间的一致性测试
Int Sch Res Notices. 2017 Feb 13;2017:1076493. doi: 10.1155/2017/1076493. eCollection 2017.
4
Prognostic and predictive implications of Sokal, Euro and EUTOS scores in chronic myeloid leukaemia in the imatinib era-experience from a tertiary oncology centre in Southern India.在印度南部一家三级肿瘤中心的伊马替尼时代，慢性髓性白血病中索卡尔、欧洲和EUTOS评分的预后及预测意义。
Ecancermedicalscience. 2016 Oct 6;10:679. doi: 10.3332/ecancer.2016.679. eCollection 2016.
5
The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single Institution Experience.哈斯福德评分可能预测慢性髓性白血病患者的分子反应：单机构经验
Dis Markers. 2016;2016:7531472. doi: 10.1155/2016/7531472. Epub 2016 Oct 12.
6
Prognostic discrimination for early chronic phase chronic myeloid leukemia in imatinib era: comparison of Sokal, Euro, and EUTOS scores in Korean population.伊马替尼时代早期慢性期慢性髓性白血病的预后判别：韩国人群中Sokal、欧洲和EUTOS评分的比较
Int J Hematol. 2014 Aug;100(2):132-40. doi: 10.1007/s12185-014-1600-4. Epub 2014 May 31.
7
European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients.欧洲治疗与预后研究评分不能预测慢性髓性白血病患者对伊马替尼的治疗反应和预后。
Cancer Sci. 2014 Jan;105(1):105-9. doi: 10.1111/cas.12321. Epub 2014 Jan 23.